Actions

Table of frequent aberrant markers in AML: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
Line 8: Line 8:
----
----


It is well recognised that marker expression in acute myeloid leukaemia may frequently include the expression of immunological markers not typically associated with myeloid lineage. Broadly, the abberant expression may include:
The key point is that AML will frequently express immunological markers not typically associated with myeloid lineage. Broadly, the abberant expression may include:


Markers of primitive phenotype that are more frequently associated with lymphoid disorders, most frequently,
Markers of primitive phenotype that are more frequently associated with lymphoid disorders, This is aknowledged in diagnostic criteria and providing diagnostic criteria are applied they do not require a changed diagnosis.
CD7 43% BCRABL TdT 7%
The most frequent "abberencies" observed in AML are:</br>
</br>(1) The expression of CD7 by nearly half of cases
</br>(2) The expression of CD19, often associated with particular AML subtypes
 
-----
 
CD19 BCRABL TdT 7%


Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage
Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage

Revision as of 17:21, 12 January 2024

The key point is that AML will frequently express immunological markers not typically associated with myeloid lineage. Broadly, the abberant expression may include:

Markers of primitive phenotype that are more frequently associated with lymphoid disorders, This is aknowledged in diagnostic criteria and providing diagnostic criteria are applied they do not require a changed diagnosis. The most frequent "abberencies" observed in AML are:

(1) The expression of CD7 by nearly half of cases
(2) The expression of CD19, often associated with particular AML subtypes

CD19 BCRABL TdT 7%

Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage CD2 CD4, 36 38 MONOCYTIC 5%

BASOPHILIC 123, 203, 11B 22

Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: CD19 30% CBF RUNX1, BCRABL CD56 CBF RUNX1 NPM1 OFTEN LACK CD34

Retrieved from ‘https://haematologyetc.co.uk/index.php?title=Table_of_frequent_aberrant_markers_in_AML&oldid=4721’